PriceTargets.com logo

IMAC - BACK Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$5.10 As of 04/25/2024 01:00 AM ET
▲ +1.61 (46.13%)

This chart shows the closing price for BACK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IMAC Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BACK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BACK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for IMAC in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $5.10.

This chart shows the closing price for BACK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in IMAC. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/6/2022Ascendiant Capital MarketsLower Target$150.00Low
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.04 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 27 very positive mentions
  • 210 positive mentions
  • 44 negative mentions
  • 10 very negative mentions
Mentions as of
9/29/2023
  • 28 very positive mentions
  • 195 positive mentions
  • 47 negative mentions
  • 23 very negative mentions
Mentions as of
10/29/2023
  • 33 very positive mentions
  • 146 positive mentions
  • 40 negative mentions
  • 15 very negative mentions
Mentions as of
11/28/2023
  • 25 very positive mentions
  • 158 positive mentions
  • 32 negative mentions
  • 14 very negative mentions
Mentions as of
12/28/2023
  • 35 very positive mentions
  • 154 positive mentions
  • 23 negative mentions
  • 15 very negative mentions
Mentions as of
1/27/2024
  • 30 very positive mentions
  • 146 positive mentions
  • 40 negative mentions
  • 4 very negative mentions
Mentions as of
2/26/2024
  • 26 very positive mentions
  • 188 positive mentions
  • 47 negative mentions
  • 19 very negative mentions
Mentions as of
3/27/2024
  • 26 very positive mentions
  • 158 positive mentions
  • 46 negative mentions
  • 18 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 26 very positive mentions
  • 158 positive mentions
  • 46 negative mentions
  • 18 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

IMAC logo
IMAC Holdings, Inc. owns and manages innovative medical advancements and care regeneration centers, and backspace clinics in the United States. The company's outpatient medical clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with sports injuries, ligament and tendon damage, and other related soft tissue conditions, as well as back, knee, and joint pains. It also provides medical treatments, regenerative, spinal decompression, chiropractic manipulation, and physical medicine and therapy. IMAC Holdings, Inc. was founded in 2000 and is headquartered in Brentwood, Tennessee.
Read More

Today's Range

Now: $5.10
Low: $3.54
High: $7.75

50 Day Range

MA: $2.28
Low: $1.28
High: $5.10

52 Week Range

Now: $5.10
Low: $1.22
High: $7.75

Volume

8,444,313 shs

Average Volume

772,909 shs

Market Capitalization

$5.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25

Frequently Asked Questions

What sell-side analysts currently cover shares of IMAC?

The following Wall Street sell-side analysts have issued stock ratings on IMAC in the last twelve months:
View the latest analyst ratings for BACK.

What is the current price target for IMAC?

0 Wall Street analysts have set twelve-month price targets for IMAC in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IMAC in the next year.
View the latest price targets for BACK.

What is the current consensus analyst rating for IMAC?

IMAC currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BACK.

What other companies compete with IMAC?

Other companies that are similar to IMAC include SenesTech, Evoke Pharma, Smart for Life, Mustang Bio and Virpax Pharmaceuticals. Learn More about companies similar to IMAC.

How do I contact IMAC's investor relations team?

IMAC's physical mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company's listed phone number is (844) 266-4622 and its investor relations email address is [email protected]. The official website for IMAC is www.imacholdings.com. Learn More about contacing IMAC investor relations.